Like with CXCL16 blockade, TGF-β neutralization has also been demonstrated to cause downregulation of tissue residency markers, leading to enhanced systemic tumor immunity, secondary tumor response, and overall survival when combined with PD-L1 blockade in mice [19]. The gene discussed is CD274; the disease is neoplasm.